BLTE · Healthcare
Belite Bio Inc - Us Adr
18/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
24
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$6.6B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqCM
About BELITE BIO INC - US ADR
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including…
Who's behind the signal
Every informed buyer we can see on BLTE, across all three feeds.
Hedge funds · 4
Duquesne Family Office (Druckenmiller)
New position
Tudor Investment (Paul Tudor Jones)
New position
Millennium Management (Englander)
Increased +2%
Citadel Advisors
Decreased −60%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
BELITE BIO INC - US ADR isn't in the top-10 model right now, but 4 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
4
Investors
2
New positions
1
Increasing
1
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.6×
% of portfolio
0.6%
Position change
NEW
0.6% of Duquesne Family Office's portfolio
Trust weight: 1.2×
% of portfolio
0.0%
Position change
NEW
0.0% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
+2%
0.1% of Millennium Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−60%
0.0% of Citadel Advisors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to BELITE BIO INC - US ADR
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell BELITE BIO INC - US ADR or any security.
Get the Weekly Update
Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime